Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Onychomycosis Market, by Type
1.4.2 North America Onychomycosis Market, by Treatment
1.4.3 North America Onychomycosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Onychomycosis Market by Type
3.1 North America Distal Subungual Market by Country
3.2 North America Proximal Subungual Market by Country
3.3 North America White Superficial Market by Country
3.4 North America Others Market by Country
Chapter 4. North America Onychomycosis Market by Treatment
4.1 North America Topical Market by Country
4.2 North America Oral Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Onychomycosis Market by Country
5.1 US Onychomycosis Market
5.1.1 US Onychomycosis Market by Type
5.1.2 US Onychomycosis Market by Treatment
5.2 Canada Onychomycosis Market
5.2.1 Canada Onychomycosis Market by Type
5.2.2 Canada Onychomycosis Market by Treatment
5.3 Mexico Onychomycosis Market
5.3.1 Mexico Onychomycosis Market by Type
5.3.2 Mexico Onychomycosis Market by Treatment
5.4 Rest of North America Onychomycosis Market
5.4.1 Rest of North America Onychomycosis Market by Type
5.4.2 Rest of North America Onychomycosis Market by Treatment
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Bausch Health Companies, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Trials and Approvals:
6.3 Bayer AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Product Launches and Expansions:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Product Launches and Product Expansions:
6.5 Sun Pharmaceutical Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional & Segmental Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional & Segmental Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Merck & Co., Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.10. Novartis AG
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Unique Offerings 